LRRC14 inhibitors are a category of chemical compounds that have been identified to interact selectively with the leucine-rich repeat-containing protein 14 (LRRC14). The LRRC14 protein is a member of the leucine-rich repeat (LRR) family, which is characterized by a specific sequence motif that forms a structural domain typically involved in protein-protein interactions. LRRC14 inhibitors work by binding to the LRRC14 protein, thereby modulating its function through a variety of possible mechanisms. The inhibition could be competitive, where the inhibitor molecules occupy the active or binding sites of the LRRC14 protein, preventing its normal interactors from binding. Alternatively, the inhibition could be allosteric, where the binding of the inhibitor induces a conformational change that reduces the protein's activity even without directly blocking the active site.
The discovery and characterization of LRRC14 inhibitors involve sophisticated techniques in biochemistry and molecular biology. This includes the use of computational molecular modeling to predict how these inhibitors will interact with the three-dimensional structure of the LRRC14 protein, as well as experimental methods such as X-ray crystallography or NMR spectroscopy to determine the exact binding mode. These compounds can be found in a variety of sources, including natural products, synthetic chemical libraries, or even as products of rational design, where the structure of the LRRC14 protein guides the synthesis of inhibitor molecules.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor impacting the MAPK pathway. Any LRR protein involvement in this pathway can be indirectly affected. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor that impacts the PI3K-AKT pathway. LRR proteins associated with this signaling might be influenced. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor. Indirect effects on LRR proteins involved in this pathway can be inferred. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor affecting the mTOR pathway. Some LRR proteins have associations with mTOR signaling. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Hedgehog pathway inhibitor. LRR proteins interacting with this pathway might be indirectly modulated. | ||||||
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $132.00 | 19 | |
Inhibitor of the Wnt/β-catenin signaling pathway. Some LRR proteins are known to interact with Wnt signaling components. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Another MEK inhibitor affecting the MAPK pathway. Potentially influences LRR proteins associated with this pathway. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
NF-κB pathway inhibitor. LRR proteins related to this pathway might be indirectly modulated. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor, affecting the PI3K-AKT pathway. LRR proteins associated might be indirectly influenced. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
ROCK inhibitor, affecting pathways related to cell motility. LRR proteins associated can be indirectly influenced. | ||||||